The user is seeking alternatives to Minoxidil due to heart issues and is considering microneedling with topical melatonin, copper peptides, resveratrol+fisetin, or stemoxydine, which reportedly have minimal side effects. They are asking for information on the effectiveness of these treatments.
Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.
The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.
A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.
Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.
A user is seeking hair loss treatments without using systemic DHT blockers like finasteride due to side effects. Suggestions include clascoterone (not FDA approved), pyrilutamide, RU58841, and low-dose topical finasteride, with a recommendation to consult a doctor.
Topical finasteride that doesn't penetrate the skin could potentially treat hair loss without side effects. Current challenges include finding a formulation that remains on the scalp without increasing blood levels.
The conversation discusses the use of autologous exosomes for hair loss, questioning their effectiveness and seeking real user experiences. The user is skeptical about the treatment's legitimacy and is looking for honest feedback on its results.
The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.
Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
Alfatradiol is used by some for hair loss, often alongside treatments like finasteride, RU58841, and minoxidil, but its effectiveness is unclear. Some users report no significant improvement, while others note reduced sebum production but experience side effects like gallbladder pain.
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
User asks where to purchase exosomes/AAPE for microneedling hair loss treatment. Links to research on hair regeneration therapy, stem cell therapy, exosome therapy, and dermal exosomes provided.
The conversation is about a person considering making their own topical finasteride to avoid side effects from oral use. They discuss potential methods and ingredients, including cayenne pepper extract, rosemary, and coconut oil, and seek advice on effectiveness and alternatives like light therapy or dermarolling.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. A user asks about alfatradiol's availability, public perception, and usage in Germany.
The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.
Topical RU58841 is discussed for hair loss treatment, with a focus on brands available in Europe that have low systemic absorption. Users suggest mixing your own solution to control vehicle and dosage, and mention different brands like Actifolic and Biolabshop.
Excessive scalp sebum, worsened by DHT, can lead to inflammation and hair loss, with clascoterone mentioned as a treatment. Diet changes seem ineffective for scalp sebum, and treatments like minoxidil and finasteride are suggested.
A user with hair loss is considering starting a business selling hair loss treatments, including RU58841, low-dose topical finasteride with optional minoxidil and tretinoin, and topical melatonin. They are also contemplating offering Pyrilutamide and other unique topicals, seeking feedback on interest and suggestions for their potential store.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
Cetirizine 10mg daily reduced hair shedding by 50% and lessened scalp itchiness. The user is considering long-term use for scalp inflammation and hair loss.
The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.
Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.
Some people have side effects from finasteride and dutasteride due to hormonal predisposition, especially if DHT dominant. Alternatives like RU58841, Pyrilutamide, and Breezula are suggested to target scalp androgen receptors without altering overall hormones.
The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.